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STUDY PROTOCOL Open Access
A feasibility randomised controlled trial of
short-term fasting prior to CAPOX
chemotherapy for stage 2/3 colorectal
cancer: SWiFT protocol
Ellie Shingler1* , Claire Perks2, Georgia Herbert1, Andy Ness1 and Charlotte Atkinson1
Abstract
Background: Capecitabine and oxaliplatin (CAPOX) chemotherapy is a standard treatment for stage 2/3 colorectal
cancer. Treatment is associated with dose-limiting toxicities such as neutropenia, vomiting, diarrhoea, and
stomatitis. Short-term fasting prior to chemotherapy may help protect normal cells from the toxic effects of
chemotherapy by allowing them to conserve energy for maintenance and repair. However, there is a lack of
evidence to support the efficacy of short-term fasting in protecting against chemotherapy-related toxicities in
humans, and it is not known whether people due to undergo chemotherapy will be willing and able to follow a
short-term fast. Preliminary data confirming this is feasible are required before adequately powered trials can be
designed and conducted.
Methods: The short-term, water only, fasting trial (SWiFT) is a two-armed feasibility randomised controlled trial,
aiming to recruit 30 people scheduled to begin routine treatment with CAPOX chemotherapy for stage 2/3
colorectal cancer. Participants will be randomly allocated, in a 1:1 ratio, to either a 36-h fast or standard dietary
advice prior to chemotherapy administration for the first 3 cycles of chemotherapy. The primary outcome measures
will assess the feasibility of the trial and include: adherence to intervention, recruitment, retention, and data
completion rates as well as the acceptability of the intervention which will be qualitatively assessed. The secondary
outcome measures aim to provide further information on possible outcomes of interest for a definitive trial and
include side effects of chemotherapy, quality of life, markers of cellular metabolism and inflammation, appetite, and
sarcopenia.
Discussion: It is not known whether it is possible to recruit to a trial of short-term fasting in this population, or
whether participants would be able to adhere to the intervention. Therefore, we aim to test the feasibility of a pre-
chemotherapy, 36-h, water-only fast in people receiving CAPOX chemotherapy for stage 2/3 colorectal cancer.
Trial registration: This trial has been registered with the ISRCTN Registry. Trial registration no: ISRCTN17994717.
Date of registration: 23 October 2018. URL: http://www.isrctn.com/ISRCTN17994717
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Background
During times of nutrient scarcity, normally functioning
body cells have the ability to switch from a state of
growth and development to a state of maintenance and
repair, which enables cells to conserve energy [1, 2]. This
process is mediated in part by a reduction in glucose, in-
sulin, and IGF-1 (Insulin-like growth factor-1) which in
turn alters cellular pathways, reducing activation of
those involved in cell proliferation and growt h[2, 3].
Conversely, as cancer is a disease of uncontrolled cell
growth, genetic mutations in tumour cells enable them to
continue to proliferate, even when nutrients are scarc e[4].
This is due to loss-of-function mutations in tumour-
suppressor genes (Rb, p53, and PTEN) which lead to
insensitivity to growth-inhibitory signals. In addition, muta-
tions in oncogenes (Ras, Akt, and mTOR) activate prolifera-
tion pathways, even in the absence of growth signal s[3].
This difference between healthy and tumour cells in
response to food restriction has been coined “Differential
Stress Resistance (DSR)”. Pre-clinical research in animal
models suggests that DSR could be exploited during
chemotherapy to limit the toxic effects of chemotherapy
in healthy cells, while leaving tumour cells susceptible to
treatment [5].
The exact mechanisms behind DSR are not fully
understood. It is believed they may be partially mediated
by the reduction in blood glucose and growth factors
such as Insulin-like Growth Factors (IGFs) brought
about by fasting. Within healthy cells, this negatively
regulates downstream cellular pathways such as the Ras/
MAPK and P13K/Akt pathways which are promoters of
cellular proliferation [3]. This allows the cells to cease
growth and convert energy to cell maintenance.
Another mechanism through which DSR may protect
healthy cells is through increased autophagy. Calorie re-
striction activates the enzyme “AMP activated protein
kinase” which increases autophagy. Autophagy can target
defective organelles to be degraded into substrate for use
in energy production and repai r[3]. Cancer is often as-
sociated with a defect in autophagic capacity as onco-
genes Akt and P13k inhibit autophagy while the tumour
suppressor gene PTEN, which loses function in tumour
cells, would usually upregulate it. The decrease in
growth factors associated with fasting may therefore lead
to the upregulation of autophagy in normal cells but not
in cancer cells, allowing them to degrade organelles for
energy us e[6].
Although some studies of fasting during chemotherapy
in cell lines and animal models have shown promising
results, it is unclear how well these findings translate to
human s[3, 7, 8].
To date, two early-stage trials on short-term fasting dur-
ing chemotherapy have been completed: A pilot trial in 13
people with breast cance r[9] and a dose-escalating safety
and feasibility trial in 20 people receiving platinum-based
chemotherapy for any cancer typ e[10]. These studies
show fasting up to 72hrs around the time of chemother-
apy administration to be safe and feasible; however, the
72hour fast may have been subject to poorer adherence.
There was some evidence of reduced haematologic toxic-
ities between groups, but limited evidence of differences
between groups for other chemotherapy side effects. How-
ever, these trials were not powered to provide evidence of
differences in toxicities between groups, so the results
should be treated as preliminary findings that require rep-
lication in adequately-powered studies.
No trials have been conducted to date in people re-
ceiving chemotherapy for colorectal cancer. A standard
treatment in the UK for stage 3 colorectal cancer (or
stage 2 colorectal cancer that is at high risk of local re-
currence) is surgical resection, followed by Capecitabine
and Oxaliplatin (CAPOX) chemotherapy [11]. Dose-
limiting toxicities for this combined regimen include
vomiting, diarrhoea, and stomatitis [12]. When used
within an RCT, withdrawal rates on CAPOX due to ad-
verse events were 21% [13]. Therefore, interventions
which aim to limit toxicities in this treatment group are
of interest. This identifies colorectal cancer as an under-
studied cancer site in terms of fasting to induce DSR as
a means of reducing chemotherapy toxicities.
Methods
Trial aim and design
Patient and public involvement were used to inform the
design of SWiFT. It is a two-armed randomised con-
trolled feasibility trial. 30 people scheduled to begin rou-
tine treatment with CAPOX chemotherapy for stage 2/3
colorectal cancer will be randomly allocated, in a 1:1 ra-
tio, to either a 36-hour fast or standard dietary advice, to
be implemented prior to each of the first three treatment
cycles.
The aim of the study is to determine whether a trial of
a 36-hour pre-chemotherapy fast is feasible in people re-
ceiving CAPOX chemotherapy for stage 2/3 colorectal
cancer.
Outcome measures
The primary outcome measures assess the feasibility of
this trial. These are
Recruitment rates
Calculated as the percentage of eligible patients re-
cruited each month, as recorded in the recruitment logs
at each site.
Adherence to intervention
Assessed by analysis of self-reported food logs, com-
pleted by participants during the 36-h fast. Participants
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will be considered to have adhered to the fast if they
consume less than 14% of their basal metabolic rate
(BMR) requirements (kcal/day calculated using the Ox-
ford equations for BMR [14]), in the 36 h prior to
chemotherapy administration. This equates to approxi-
mately 200 kcal per day, depending on age and gender.
The aim of using a cut-off of 14% BMR is to allow
participants to consume small amounts of food if they
need to mitigate any side effects of fasting, while keeping
the participant in the metabolically altered state associ-
ated with fasting. This cut-off has been used in previous
trials of fasting [10]. To encourage participants to only
consume a small number of calories, a list of 50 kcal
snacks will be provided. The percentage of adherent par-
ticipants will be reported for each cycle. Reasons for
non-adherence will also be recorded.
Retention rates
Calculated as the number of participants who completed
data collection for each fasting cycle (both self-reported data
and clinical care team recorded data associated with that
cycle) divided by the number of participants randomised.
Acceptability and tolerability of the intervention
Qualitatively assessed through in-depth semi-structured
interviews with trial participants.
Data completion rates
Completeness of data will be assessed for all measures at
each cycle. The secondary outcome measures aim to
provide further information on possible outcomes of
interest in a definitive trial. Including these in the feasi-
bility trial will allow for the data collection methods to
be assessed as well as providing information on the vari-
ance of each outcome. The impact of fasting on these
measures could then be tested in a suitably powered
trial. The secondary outcome measures are:
Side effects of chemotherapy
Measured using the Patient-Reported Outcomes version
of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE™) [15], Full-blood count (FBC) and
blood chemistry analysis. Short-term dietary fasting may
result in differential stress resistance between normal
and tumour cells, which may render tumour cells more
susceptible to chemotherapy than normal cells. Patient-
reported side effects will be collected on day 1 of each
cycle (prior to chemotherapy administration) and at
home on days 3 and 7 (via participant-completed ques-
tionnaires) to capture the transient nature of side effects.
Data will also be recorded on whether participants com-
pleted their first 3 cycles of chemotherapy and reasons
for dose reductions/delays/early termination if they
occurred.
Quality of Life
Measured using the EQ-5D-5L health-related quality of
life instrument [16]. This would be used to explore
whether fasting or its impact on chemotherapy side ef-
fects, increases quality of life (QoL).
Haematologic toxicities
Assessed using routine FBC data collected prior to each
round of chemotherapy and classified according to
CTCAE criteria [17].
Markers of cellular metabolism
Measures will include glucose, insulin, IGF-I, IGF-II,
IGF-binding protein (IGFBP)-2 and IGFBP-3. These will
be used to study the effect of the fast on markers of cel-
lular metabolism. They will also be considered in con-
junction with self-reported dietary intake to explore
adherence to the intervention, as the level of these
markers would be expected to be reduced in adherent
participants. Baseline samples will be collected prior to
fasting when participants attend for routine pre-
chemotherapy blood tests (approx. 4 days prior to cycle
1). Follow-up samples will be collected immediately
prior to chemotherapy administration at cycles 1 and 3.
Markers of inflammation
C-reactive protein (CRP) will be measured at baseline
(pre-fast) and prior to chemotherapy administration at
cycles 1 and 3. In a full-powered trial, this would be used
to explore whether fasting reduces inflammation.
Appetite
Self-reported on visual analogue scales [18]. As chemo-
therapy can alter taste and appetite [19], measuring ap-
petite is of interest to explore whether fasting negates
reduced appetite through decreased treatment side
effects.
Sarcopenia
Assessed using computerised tomography (CT) and
handgrip dynamometer [20]. Single axial images of the
third lumbar (L3) level muscle mass, taken from pre-
chemotherapy staging and follow-up CT scans con-
ducted as part of routine care, will be analysed for body
composition using SliceOMatic software [21]. Handgrip
strength will be measured three times in the dominant
hand, while the participant is in a seated position, arms
supported at right angles, and feet on the floor. Mea-
surements will be taken by the research site’s clinical
trial officer/research nurse who will be trained in follow-
ing the trial’s standard operating procedure for measur-
ing handgrip strength. The mean of the three measures
will be used to assess handgrip strength, using cut-off
values defined by the European Working Group on
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Sarcopenia in Older People (EWGSOP) to identify low
grip strength [22]. These measures will allow us to in-
form future trials on the prevalence of sarcopenia in this
population and explore the safety of fasting in relation
to this condition.
Participants
The feasibility study will aim to recruit 30 participants
from two NHS hospital sites in the West of England. Re-
cruitment will take place between September 2019 and
September 2020. As this is a feasibility trial, it is not ap-
propriate to perform formal power calculations. Instead
a sample size of 30 was chosen based on the practical-
ities of conducting an early-stage intervention trial
within the scope of a Ph.D. project. This sample size will
also allow for the estimation of parameters for potential
primary outcomes in a definitive trial, helping to inform
future sample size calculations [23].
Eligible participants will provide written informed con-
sent, taken by a member of the site-based research team.
Participants will be deemed eligible if they are aged ≥ 18
years with histologically confirmed stage 2/3 colorectal
cancer, are due to undergo treatment with adjuvant
CAPOX chemotherapy, have an ECOG performance sta-
tus ≤ 2 and are able to provide written informed consent.
People will be excluded if they have a clinical diagnosis
of cachexia or diabetes, a body mass index (BMI) ≤ 18.5
kg/m2, history of an eating disorder, or drug/alcohol
abuse are participating in another study that may affect
the outcomes of this feasibility trial or are unable to
speak/understand English.
Treatment discontinuation will be at the discretion of
the principal investigator or other attending clinician or
the participant themselves. All participants who with-
draw from the trial intervention will be followed up as
per the follow-up schedule until trial completion. The
exception to this will be if a participant explicitly with-
draws consent for any further trial follow-up.
Randomisation and allocation
Randomisation will be completed in a 1:1 ratio using
random permuted blocks, by a secure online randomisa-
tion system.
Blinding of the participant to the outcome of random-
isation will not be possible, due to the nature of this
intervention. However, outcome assessors of the markers
of cellular metabolism will remain blind to participants’
random allocation.
Trial arms
Following randomisation, participants will be given ver-
bal and written instructions related to their allocated
trial arm by a member of the trial team. These instruc-
tions will detail how and when to complete the self-
reported data and, for the intervention arm, how and
when to implement the fast.
Participants randomised to the intervention arm will
undertake a 36-h water-only fast, immediately prior to
chemotherapy administration for the first 3 cycles. A de-
crease in IGF-I levels in response to a short-term fast in
humans is seen within 36–120 h of fasting [3]. As previ-
ous research has suggested that longer fasts may be sub-
ject to poorer adherence [10], we have selected a 36-h
fast prior to each of the first 3 cycles of chemotherapy.
This aims to find the balance between implementing a
fast that is long enough to alter metabolic pathways
whilst keeping participant burden to a minimum.
Participants randomised to the control arm of the trial will
receive standard dietary guidance/advice as per local stand-
ard practice. This may include verbal or written information
on the diet and effects of chemotherapy on appetite.
Study schedule
The SPIRIT figure is shown in Table 1, which outlines the
study schedule and the SPIRIT checklist has been pro-
vided as an Additional file 1. Baseline assessments will
take place when the patient attends their screening visit,
following successful screening and enrolment. The inter-
vention will be implemented for the first 3 cycles of their
chemotherapy schedule. Follow-up data will be collected
on days 1, 3, and 7 of each cycle. Adverse events and con-
comitant medication will be monitored throughout trial
participation. At the end of their trial participation, each
participant will resume their usual care pathway.
The end of the trial will be defined as the completion
of data queries, and sample and data analysis.
Embedded qualitative study
Participants will be invited to take part in one semi-
structured qualitative interview once they have com-
pleted the trial. These will be conducted face-to-face in
the clinic. However, telephone interviews will be ar-
ranged where face-to-face interviews are not possible.
Interviews will follow a topic guide, which covers
topics such as dietary guidance received, experience of
randomisation, tolerability of the intervention/experi-
ence of taking part as a “control”, and experience of the
data collection methods. It will also discuss any barriers
or enabling factors that participants experienced in ad-
hering to the fast, with the view to informing future tri-
als of fasting interventions. However, an open discussion
will be promoted, and the topic guide will be continually
reviewed throughout the interview process to ensure it
covers any emerging topics of interest.
Biological specimens
All human tissue samples will be collected, used, and
stored in accordance with the Human Tissue Act 2004.
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Table 1: Trial schedule
C = cycle; CRP = C-reactive protein; D = Dday, where −1 is the day prior to chemotherapy and 1 is the day of chemotherapy; FBC = full-blood count; Pro CTCAE =
Patient reported outcomes-Common Terminology Criteria for Adverse Events; QoL = quality of life
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FBC and blood chemistry data will be collected from
routine samples analysed in NHS labs as per standard
practice. This data will be collected from participant
medical records by a member of their clinical care team
or research team member based on their site.
As per the trial schedule (Table 1), additional baseline
and follow-up samples obtained immediately prior to
chemotherapy administration at cycles 1 and 3 will be ana-
lysed within the NHS labs for glucose, insulin, and CRP.
Additional blood samples will be collected at baseline
and chemotherapy day 1 visits for cycles 1 and 3 for ana-
lysis of IGF-I, IGF-II, IGFBP-2, and IGFBP-3. Following
collection, serum tubes will be inverted 8–10 times, then
allowed to sit at room temperature, in the dark (e.g.
within an envelope) for 30–60 min to clot. Samples will
be centrifuged at 2500 rpm for 15 min, and the serum
pipetted off the top for storage. This will be aliquoted
into 1.5 ml Eppendorf tubes (1ml per tube) for freezing
(at − 80 °C) and storage at the NHS site until transfer to
the University of Bristol laboratories for analysis at the
end of the trial.
Quantitative data analysis
Rates and confidence intervals will be reported for
the primary outcomes. Baseline characteristics in each
trial arm will be reported. Secondary outcome data
will be summarised using means (standard deviations)
or medians (inter-quartile ranges) as appropriate for
continuous variables, and frequencies with percent-
ages (n, %) for categorical variables, to inform out-
comes of interest and sample size calculations in
future trials. All quantitative data will be analysed in
STATA 15 [24].
Qualitative data analysis
Audio recordings of the interviews will be transcribed
verbatim by a sponsor approved transcription company.
The anonymised data will be analysed using the frame-
work method, a form of thematic analysis [25]. A coding
index, based on the interview topic guide, will be used to
sort the data into themes. An inductive approach to ana-
lysis will be used, allowing emergent themes to alter the
coding as the analysis progresses. Coding will be com-
pleted by a single researcher, then reviewed by a second
researcher to ensure both consistency of coding and
grounding in the original data. Any inconsistencies in
themes or coding will be discussed and resolved between
the two researchers. This process will take place in par-
allel with the data collection to allow any emerging
themes to be further explored in subsequent interviews.
A framework matrix will then be created using partici-
pants’ responses to each theme. Qualitative data analysis
will be assisted by Nvivo 10 software [26].
Discussion
This is the first study of short-term fasting in people due
to undergo chemotherapy for colorectal cancer. Fasting
during the treatment of cancer is an area of growing re-
search interest, due to the findings of pre-clinical re-
search in animal, cell line, and yeast models. This
research has identified fasting as a potential tool for re-
ducing the toxicities associated with cancer treatments
such as chemotherapy and radiotherapy, as well as po-
tentially improving tumour response and survival rates.
However, although some studies of fasting during
chemotherapy in pre-clinical models have shown prom-
ising results, it is unclear how well these findings trans-
late to humans.
SWiFT will allow us to test the feasibility of conduct-
ing a fasting intervention in people undergoing chemo-
therapy for colorectal cancer, a population previously
unstudied in this area. The embedded interview study
will also allow us to qualitatively assess patient experi-
ences of the intervention and data collection methods
used in the trial. We will use validated questionnaires to
collect data on treatment side effects experienced by trial
participants. Although not powered to determine effects
of the fast on these treatment toxicities, collecting data
on the secondary outcomes such as chemotherapy side
effects and markers of cellular metabolism, will help to
inform sample size calculations in future trials.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-019-0505-7.
Additional file 1. SWiFT SPIRIT checklist.
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